John Wiley & Sons WLYB

NYSE WLYB

$48.38 +0.00 (+0.00%)

As of: Sep 9, 2026 · 9:46 AM EDT

Key Stats

Market Cap2.46 Bn

P/E12.39

P/S1.47

Div. Yield0.03

Total Debt (Qtr)1.31 Bn

Revenue Growth (1y) (Qtr)-2.63

Add ratio to table…

About

John Wiley & Sons Inc is a global leader in research and learning providing content services platforms and knowledge networks to researchers students instructors professionals institutions and corporations The company operates as a predominantly digital enterprise with 83 percent of its adjusted revenue for fiscal year 2025 generated by digital products and services Its core activities include publishing scientific technical medical and scholarly journals offering digital courseware and assessments and delivering content platforms and services that support research and professional development Wiley is incorporated in the state of New York and has been operating since its founding in 1807

The company generates revenue through the sale of publishing content digital platforms and related services across its operational segments Research revenue comes from journal subscriptions transformational agreements open access publishing and licensing and ancillary products Learning revenue is derived from print and digital publishing digital courseware assessments and licensing and ancillary products The Held for Sale or Sold segment includes non-core businesses that were either held for sale or divested during the fiscal year Revenue is generated globally through direct sales to institutions consortia and professionals as well as through independent agents retailers and digital platforms

The company operates through the following segments: Research Learning and Held for Sale or Sold

Research supports researchers professionals and learners in the discovery and use of research knowledge It provides over 1800 scientific technical medical and scholarly journals along with related content and services in physical sciences and engineering health sciences social sciences and humanities and life sciences Research customers include academic corporate government and public libraries funders of research researchers scientists clinicians engineers technologists scholarly and professional societies and students and professors Research products are sold globally through direct agreements with research libraries and library consortia independent subscription agents and direct sales to researchers and professional society members For fiscal year 2025 approximately 96 percent of Research revenue is generated by digital and online products and services Research publishing centers are located in Australia China Germany India the UK and the US.
Learning includes Academic and Professional and offers scientific professional and education print and digital books digital courseware and assessment services for businesses and professionals Primary categories served include business and leadership technology behavioral health engineering architecture science and professional education Products are sold through brick-and-mortar and online retailers wholesalers college bookstores individual practitioners corporations distributor networks and government agencies Publishing centers are located in Australia Germany India the UK and the US For fiscal year 2025 approximately 60 percent of Learning revenue is from digital and online products and services.
Held for Sale or Sold primarily consists of non-core businesses that were classified as held for sale until the date of sale as well as other businesses that were sold This includes University Services sold on January 1 2024 Wiley Edge sold on May 31 2024 except its India operations which were sold on August 31 2024 CrossKnowledge sold on August 31 2024 and other businesses sold in fiscal years 2024 and 2023 CrossKnowledge previously offered online learning and training solutions for global corporations and small and medium-sized enterprises Wiley Edge sourced students and professionals for technology and banking services careers and placed them with financial institutions technology companies and government agencies.

Wiley is one of the world’s largest publishers and a global leader in research and learning It maintains a strong position in the academic publishing industry with a top three ranking in terms of citations received according to the 2024 release of the Journal Citation Reports The company’s competitive advantages include its long-standing publishing alliances with prestigious societies such as the American Cancer Society the American Heart Association and the American Geophysical Union its digital content platform Wiley Online Library and its focus on high-growth areas such as open access publishing and content licensing for artificial intelligence models

Wiley serves a diverse customer base including researchers students instructors professionals institutions and corporations Specific customer types include academic corporate government and public libraries funders of research scientists clinicians engineers technologists scholarly and professional societies college bookstores individual practitioners corporations and government agencies The company also works with professional societies that sponsor or own journals and receive royalties or financial consideration for their partnership

Investment Thesis

▲ Bull case

Wiley's strategic partnerships and acquisitions are creating powerful synergies between its legacy content assets and emerging AI-driven revenue streams, positioning the company at the forefront of the healthcare and scientific AI revolution. The OpenEvidence partnership integrates Wiley's peer-reviewed medical content—including the Cochrane Database of Systematic Reviews and over 400 journals—into a platform trusted by more than 40% of U.S. physicians for point-of-care decisions, directly addressing the 17-year lag between research publication and clinical adoption. This collaboration transforms Wiley from a content provider into an essential infrastructure layer for clinical decision support, with recurring licensing revenue that scales as physician adoption grows and medical knowledge continues to double every 73 days. Simultaneously, the appointment of Armughan Rafat as Chief AI and Data Services Officer accelerates Wiley's ability to monetize its vast proprietary data assets, such as the Wiley Registry of Mass Spectral Data 2026 containing over 915,500 validated spectra, which serves as a critical validation layer for AI-driven workflows in pharmaceuticals, forensics, and materials science. These initiatives are not incremental; they represent a structural shift where Wiley's century-old content moat becomes the training ground and verification engine for enterprise AI, creating high-margin, sticky revenue streams that are largely insulated from traditional publishing cyclicality. The market is underestimating how these AI and data services—bolstered by recent LLMs licensing deals and corporate R&D partnerships—are evolving into a durable growth engine with expansion potential far beyond current guidance, especially as Wiley leverages its Executive Leadership Team additions like Jessica Kowalski from Microsoft to scale AI-enabled research publishing globally.
Wiley's capital allocation strategy reflects a disciplined, shareholder-friendly approach that is significantly enhancing intrinsic value while funding transformative growth initiatives. The company raised its quarterly dividend to $0.355 per share (equivalent to $1.42 annually), marking the 32nd consecutive year of dividend increases—a testament to resilient cash flow generation and management's commitment to returning capital even amid strategic investments. Concurrently, Wiley increased its Fiscal 2026 share repurchase authorization to $100 million, up from $60 million in FY25, signaling confidence in its ability to generate excess cash while investing in high-return opportunities like the Emerald acquisition. This £337 million (USD 452 million) all-cash deal adds nearly 500 journal brands and 8,000 book titles, expanding Wiley's portfolio to approximately 2,500 titles and establishing leadership in high-growth social sciences domains like economics, business, and finance—areas where corporate AI adoption is accelerating rapidly. Emerald brings 92% recurring subscription revenue, with 85% of revenue outside North America, providing immediate diversification and a foundation for cross-selling Wiley's AI and data services to new corporate and academic audiences. The acquisition is expected to generate over USD 85 million in revenue in its first year with mid-single-digit growth, while Wiley targets approximately USD 30 million in annual run-rate cost synergies by year three. This combination of organic growth in Research and AI, bolt-on acquisitions that enhance content depth and AI training data, and aggressive shareholder returns creates a compounding effect where each initiative strengthens the others—yet the market appears to be valuing Wiley primarily on its legacy Research and Learning segments, overlooking the accelerating contribution from its AI, data services, and strategic M&A pipeline.

Wiley's strategic partnerships and acquisitions are creating powerful synergies between its legacy content assets and emerging AI-driven revenue streams, positioning the company at the forefront of the healthcare and scientific AI revolution. The OpenEvidence partnership integrates Wiley's peer-reviewed medical content—including the Cochrane Database of Systematic Reviews and over 400 journals—into a platform trusted by more than 40% of U.S. physicians for point-of-care decisions, directly addressing the 17-year lag between research publication and clinical adoption. This collaboration transforms Wiley from a content provider into an essential infrastructure layer for clinical decision support, with recurring licensing revenue that scales as physician adoption grows and medical knowledge continues to double every 73 days. Simultaneously, the appointment of Armughan Rafat as Chief AI and Data Services Officer accelerates Wiley's ability to monetize its vast proprietary data assets, such as the Wiley Registry of Mass Spectral Data 2026 containing over 915,500 validated spectra, which serves as a critical validation layer for AI-driven workflows in pharmaceuticals, forensics, and materials science. These initiatives are not incremental; they represent a structural shift where Wiley's century-old content moat becomes the training ground and verification engine for enterprise AI, creating high-margin, sticky revenue streams that are largely insulated from traditional publishing cyclicality. The market is underestimating how these AI and data services—bolstered by recent LLMs licensing deals and corporate R&D partnerships—are evolving into a durable growth engine with expansion potential far beyond current guidance, especially as Wiley leverages its Executive Leadership Team additions like Jessica Kowalski from Microsoft to scale AI-enabled research publishing globally.
Wiley's capital allocation strategy reflects a disciplined, shareholder-friendly approach that is significantly enhancing intrinsic value while funding transformative growth initiatives. The company raised its quarterly dividend to $0.355 per share (equivalent to $1.42 annually), marking the 32nd consecutive year of dividend increases—a testament to resilient cash flow generation and management's commitment to returning capital even amid strategic investments. Concurrently, Wiley increased its Fiscal 2026 share repurchase authorization to $100 million, up from $60 million in FY25, signaling confidence in its ability to generate excess cash while investing in high-return opportunities like the Emerald acquisition. This £337 million (USD 452 million) all-cash deal adds nearly 500 journal brands and 8,000 book titles, expanding Wiley's portfolio to approximately 2,500 titles and establishing leadership in high-growth social sciences domains like economics, business, and finance—areas where corporate AI adoption is accelerating rapidly. Emerald brings 92% recurring subscription revenue, with 85% of revenue outside North America, providing immediate diversification and a foundation for cross-selling Wiley's AI and data services to new corporate and academic audiences. The acquisition is expected to generate over USD 85 million in revenue in its first year with mid-single-digit growth, while Wiley targets approximately USD 30 million in annual run-rate cost synergies by year three. This combination of organic growth in Research and AI, bolt-on acquisitions that enhance content depth and AI training data, and aggressive shareholder returns creates a compounding effect where each initiative strengthens the others—yet the market appears to be valuing Wiley primarily on its legacy Research and Learning segments, overlooking the accelerating contribution from its AI, data services, and strategic M&A pipeline.

▼ Bear case

Despite Wiley's optimistic narrative around AI and data services, the company faces significant execution risks in monetizing its content through emerging technology partnerships, particularly as large language model (LLM) developers and corporate R&D teams increasingly seek to train models on scraped or synthetic data rather than licensing proprietary archives. The OpenEvidence partnership, while strategically sound, relies on physicians continuing to trust and use a third-party platform for point-of-care decisions—a behavior that remains unproven at scale and vulnerable to disruption if major EHR vendors (like Epic or Cerner) embed similar AI functionality directly into clinical workflows, bypassing the need for external tools like OpenEvidence. Similarly, Wiley's push to commercialize AI-ready content through Armughan Rafat's leadership assumes that corporate clients will pay premiums for access to its spectral databases or journal archives when cheaper, broader datasets (even if less accurate) are readily available via open-source platforms or web-scraped corpora. The company's claim of surpassing $100 million in lifetime AI revenue lacks context on recurrence rates, customer concentration, or gross margins—raising concerns that much of this revenue may stem from one-time licensing deals rather than sustainable, high-margin SaaS models. Furthermore, Wiley's guidance for Fiscal 2026 assumes high-end Adjusted EBITDA margin expansion to 25.5–26.5% and Adjusted EPS of $3.90–$4.35, yet its Learning segment continues to show weakness, with Q3 FY26 revenue declining 5% year-over-year in constant currency, reflecting ongoing pressure from the used textbook market, digital adoption shifts, and seasonal volatility. If margin expansion in Research fails to offset persistent Learning segment drag—and if AI monetization falls short of expectations—the company may struggle to deliver on its elevated earnings targets, especially given its reliance on non-GAAP adjustments that exclude divestiture impacts and restructuring costs.
The Emerald acquisition, while strategically compelling on paper, introduces substantial integration and valuation risks that could undermine Wiley's financial flexibility and dilute shareholder returns if synergies fail to materialize as expected. Priced at £337 million (USD 452 million), the deal values Emerald at a significant premium given its expected FY26 revenue of over USD 85 million—implying a forward revenue multiple exceeding 5x, which is high for a subscription-based publishing business even with 92% recurring revenue and strong international exposure. Wiley expects to realize approximately USD 30 million in annual run-rate cost synergies by year three, but historical precedent in scholarly publishing M&A suggests that cost savings from combining editorial, production, and distribution functions are often harder to achieve than projected due to cultural integration challenges, duplicated systems, and resistance from academic societies tied to Emerald's brand. Moreover, the acquisition assumes that Emerald's content will meaningfully enhance Wiley's AI and data analytics offerings, yet there is no clear evidence that social science research (Emerald's core strength in economics, business, and finance) is currently in high demand for training LLMs or powering AI-driven R&D pipelines compared to biomedical or physical sciences content—raising questions about the strategic fit beyond scale. The all-cash nature of the transaction also reduces Wiley's financial flexibility, particularly as it continues to fund dividend increases and share buybacks; if Emerald underperforms or integration costs exceed estimates, the company may be forced to cut back on shareholder returns or take on debt, undermining the very financial discipline it has cultivated. Market participants may be overlooking these execution risks, focusing instead on the headline growth potential while underestimating the operational complexity of integrating a culturally distinct, UK-based publisher with deep ties to European academic institutions.

Despite Wiley's optimistic narrative around AI and data services, the company faces significant execution risks in monetizing its content through emerging technology partnerships, particularly as large language model (LLM) developers and corporate R&D teams increasingly seek to train models on scraped or synthetic data rather than licensing proprietary archives. The OpenEvidence partnership, while strategically sound, relies on physicians continuing to trust and use a third-party platform for point-of-care decisions—a behavior that remains unproven at scale and vulnerable to disruption if major EHR vendors (like Epic or Cerner) embed similar AI functionality directly into clinical workflows, bypassing the need for external tools like OpenEvidence. Similarly, Wiley's push to commercialize AI-ready content through Armughan Rafat's leadership assumes that corporate clients will pay premiums for access to its spectral databases or journal archives when cheaper, broader datasets (even if less accurate) are readily available via open-source platforms or web-scraped corpora. The company's claim of surpassing $100 million in lifetime AI revenue lacks context on recurrence rates, customer concentration, or gross margins—raising concerns that much of this revenue may stem from one-time licensing deals rather than sustainable, high-margin SaaS models. Furthermore, Wiley's guidance for Fiscal 2026 assumes high-end Adjusted EBITDA margin expansion to 25.5–26.5% and Adjusted EPS of $3.90–$4.35, yet its Learning segment continues to show weakness, with Q3 FY26 revenue declining 5% year-over-year in constant currency, reflecting ongoing pressure from the used textbook market, digital adoption shifts, and seasonal volatility. If margin expansion in Research fails to offset persistent Learning segment drag—and if AI monetization falls short of expectations—the company may struggle to deliver on its elevated earnings targets, especially given its reliance on non-GAAP adjustments that exclude divestiture impacts and restructuring costs.
The Emerald acquisition, while strategically compelling on paper, introduces substantial integration and valuation risks that could undermine Wiley's financial flexibility and dilute shareholder returns if synergies fail to materialize as expected. Priced at £337 million (USD 452 million), the deal values Emerald at a significant premium given its expected FY26 revenue of over USD 85 million—implying a forward revenue multiple exceeding 5x, which is high for a subscription-based publishing business even with 92% recurring revenue and strong international exposure. Wiley expects to realize approximately USD 30 million in annual run-rate cost synergies by year three, but historical precedent in scholarly publishing M&A suggests that cost savings from combining editorial, production, and distribution functions are often harder to achieve than projected due to cultural integration challenges, duplicated systems, and resistance from academic societies tied to Emerald's brand. Moreover, the acquisition assumes that Emerald's content will meaningfully enhance Wiley's AI and data analytics offerings, yet there is no clear evidence that social science research (Emerald's core strength in economics, business, and finance) is currently in high demand for training LLMs or powering AI-driven R&D pipelines compared to biomedical or physical sciences content—raising questions about the strategic fit beyond scale. The all-cash nature of the transaction also reduces Wiley's financial flexibility, particularly as it continues to fund dividend increases and share buybacks; if Emerald underperforms or integration costs exceed estimates, the company may be forced to cut back on shareholder returns or take on debt, undermining the very financial discipline it has cultivated. Market participants may be overlooking these execution risks, focusing instead on the headline growth potential while underestimating the operational complexity of integrating a culturally distinct, UK-based publisher with deep ties to European academic institutions.

Geographical Breakdown of Revenue (2026)

Peer group

Peer Comparison

Companies in the Publishing

S.No.	Ticker	Company	match	Market Cap	P/E	P/S	Total Debt (Qtr)
1	NWS	News Corp	primary	18.43 Bn	24.80	2.04	2.00 Bn
2	NYT	New York Times Co	primary	10.84 Bn	27.59	3.64	-
3	KRKR	36Kr Holdings Inc.	primary	6.01 Bn	-336.82	86.07	0.00 Bn
4	WLYB	John Wiley & Sons, Inc.	primary	2.46 Bn	12.39	1.47	1.31 Bn
5	MH	McGraw Hill, Inc.	primary	2.34 Bn	25.27	1.11	2.57 Bn
6	ZD	Ziff Davis, Inc.	primary	2.01 Bn	3.06	1.52	1.02 Bn
7	TDAY	USA TODAY Co., Inc.	primary	0.92 Bn	-19.49	0.41	0.71 Bn
8	DJCO	Daily Journal Corp	primary	0.88 Bn	23.25	8.90	0.00 Bn

John Wiley & Sons WLYB

About

Investment Thesis

Segments Breakdown of Revenue (2026)

Geographical Breakdown of Revenue (2026)

Peer Comparison

Create an account

Sign In

Reset Password